In response to the growing diabetes epidemic and increasing demand for insulin around the world, pharmaceutical company Eli Lilly and Co. announced Thursday it will invest more than $700 million to enhance its insulin manufacturing capacity in Puerto Rico, France and China, as well as in its Indianapolis global headquarters.
Private investment firm Graham Partners has acquired a majority stake in Comar Inc., a manufacturer of packaging solutions and liquid dispensing products for the pharmaceutical, diagnostic, health, and personal care markets with plants in New Jersey and Cayey, where it employs 50.